Sagent Pharmaceuticals, Inc. is a specialty and generic pharmaceutical company. The Company is a provider of pharmaceuticals to the hospital market, which it sells primarily throughout North America. It is focused on developing, manufacturing, sourcing and marketing injectable pharmaceutical products to the hospital market. It operates through two segments: Sagent US, consisting of the Company's operations in the United States and the Sagent (China) Pharmaceuticals Co. Ltd. (SCP) manufacturing facility, and Omega, which is focused on the Canadian and international markets. It offers a range of products across anti-infective, oncology and critical care indications in a range of presentations, including single and multi-dose vials, pre-filled ready-to-use syringes and premix bags. Its Sagent US product portfolio includes approximately 60 marketed products that it offers in over 180 presentations, and its Omega segment offers over 50 products.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
SymbolNASDAQ:SGNT
CUSIP78669210
Phone+1-847-9081604
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-0.72%
Return on Equity-0.81%
Return on Assets-0.59%
Miscellaneous
EmployeesN/A
Outstanding Shares33,090,000
Market Cap$0.00
Sagent Pharmaceuticals (NASDAQ:SGNT) Frequently Asked Questions
What is Sagent Pharmaceuticals' stock symbol?
Sagent Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGNT."
How were Sagent Pharmaceuticals' earnings last quarter?
Sagent Pharmaceuticals Inc (NASDAQ:SGNT) released its quarterly earnings results on Tuesday, May, 3rd. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.01 by $0.16. The company had revenue of $67.30 million for the quarter, compared to analyst estimates of $74.30 million. Sagent Pharmaceuticals had a negative net margin of 0.72% and a negative return on equity of 0.81%. Sagent Pharmaceuticals's revenue for the quarter was down 17.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.04 EPS. View Sagent Pharmaceuticals' Earnings History.
Has Sagent Pharmaceuticals been receiving favorable news coverage?
News stories about SGNT stock have been trending somewhat positive on Thursday, Accern Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sagent Pharmaceuticals earned a media and rumor sentiment score of 0.18 on Accern's scale. They also assigned news headlines about the company an impact score of 46.57 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days. View Recent Headlines for Sagent Pharmaceuticals.
How do I buy shares of Sagent Pharmaceuticals?
Shares of SGNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sagent Pharmaceuticals' stock price today?
One share of SGNT stock can currently be purchased for approximately $21.76.
How can I contact Sagent Pharmaceuticals?
Sagent Pharmaceuticals' mailing address is 1901 N Roselle Rd Ste 700, SCHAUMBURG, IL 60195-3194, United States. The company can be reached via phone at +1-847-9081604.
MarketBeat Community Rating for Sagent Pharmaceuticals (NASDAQ SGNT)
MarketBeat's community ratings are surveys of what our community members think about Sagent Pharmaceuticals and other stocks. Vote "Outperform" if you believe SGNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SGNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
